| Identification | Back Directory | [Name]
GSK 625433 | [CAS]
885264-71-1 | [Synonyms]
GSK 625433
GSK 625433 USP/EP/BP
GSK625433,GSK 625433
HLQXYDHLDZTWDW-KAWPREARSA-N
(4R,5S)-rel-1-[4-(1,1-Dimethylethyl)-3-methoxybenzoyl]-4-(methoxymethyl)-2-(1H-pyrazol-1-ylmethyl)-5-(2-thiazolyl)-D-proline
D-Proline, 1-[4-(1,1-dimethylethyl)-3-methoxybenzoyl]-4-(methoxymethyl)-2-(1H-pyrazol-1-ylmethyl)-5-(2-thiazolyl)-, (4R,5S)-rel- | [Molecular Formula]
C26H32N4O5S | [MDL Number]
MFCD11977294 | [MOL File]
885264-71-1.mol | [Molecular Weight]
512.628 |
| Chemical Properties | Back Directory | [Boiling point ]
703.747±60.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.303±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [pka]
4.427±0.10(predicted) |
| Hazard Information | Back Directory | [Uses]
GSK 625433 is a hepatitis C virus inhibitor[1]. | [References]
[1] Chabour I, et al. Dual chiral silver catalyst in the synthetic approach to the core of hepatitis C virus inhibitor GSK 625433 using enantioselective 1, 3-dipolar cycloaddition of azomethine ylides and electrophilic alkenes. Tetrahedron: Asymmetry, 2017, 28(10): 1423-1429. |
|
|